Overview

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate whether the time to progression for the DOXIL and docetaxel combination therapy group was superior to that of the group treated with docetaxel monotherapy in participants with advanced breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
Docetaxel
Doxorubicin
Liposomal doxorubicin
Pharmaceutical Solutions